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were later transitioned to CHO-derived enzyme (Myozyme). 
Weekly infusions of 10 mg/kg resulted in an only slight increase 
of muscle GAA activity. After 12 to 24 weeks of therapy the 
ERT dosage was increased to 20 mg/kg weekly. At baseline, 
all  patients  were  wheelchair-bound  and  the  2  older  patients 
needed ventilatory support; after 72 weeks of treatment all pa-
tients showed stabilized pulmonary function, were less fatigued 
whereas laboratory tests revealed a decrease of creatine kinase, 
transaminases and LDH levels. The distal muscles responded 
better than the proximal ones. The best clinical response was 
observed in the youngest patient, who was less affected when 
he began therapy. The stabilization of pulmonary and muscle 
function as well as the improvement in quality of life during the 
first 3 years of therapy were maintained throughout the 5 year 
extension period (1).
An observational, open-label, follow-up study of 3 juve-
nile  Pompe  patients  presenting  without  cardiomyopathy  has 
been reported in 2010. Those three patients received ERT with 
three different protocols with dosages ranging from 10-40 mg/
kg every other week. The less affected patient (3 years and 8 
months at start) showed a significant improvement of muscle 
function with no regression during 70 weeks of follow-up. The 
second patient (2 years and 8 months at start) initially showed 
improved muscle functions, motor skills, and development, but 
he reached a plateau around week 114 despite an increased dose 
during the following 35 weeks. The third patient (19 years and 9 
months at start) had severe skeletal muscle condition at baseline 
and died suddenly after only 20 weeks of ERT (2).
An open label trial of ERT was conducted in 44 late-onset 
GSD II patients with variable disease severity. Alglucosidase 
alfa was administred at the standard dose (20 mg/kg every other 
week). Clinical assessments included serial arm function tests 
(AFT), Walton Gardner Medwin scale (WGMS), timed 10-m 
walk tests, four-stair climb tests, modified Gowers’ maneuvers, 
6-min walk test (6MWT), MRC sum score, forced vital capac-
ity (FVC), creatine kinase (CK) levels and SF-36 self-reporting 
questionnaires. After  12  months  of  ERT,  the  authors  found 
significant  changes  of  the  modified  Gowers’  maneuvers,  the 
6-min walk test and the CK levels, while all other tests were 
unchanged. No serious adverse events occurred and none of the 
patients died or required de novo ventilation (3).
The  first  randomized,  double-blind,  placebo-controlled 
phase III study in late onset GSD II (LOTS) enrolled, in the 
United States and Europe, 90 patients ambulatory and free of 
invasive ventilation. They were randomly assigned to receive 
biweekly, for 78 weeks,.i.v. alglucosidase alfa at standard doses 
or placebo. Study primary endpoints were the evaluations of 
6MWT and the pulmonary function. After that treatment the pa-
tients showed an improved walking distance and stabilization of 
pulmonary function (4).
Most recently, Angelini et al. studied the efficacy of ERT in 
a large cohort of Italian patients treated from 12 months up to 54 
months. While the LOTS study included only walking and non-
ventilated patients, they enrolled also severely affected patients 
with assisted ventilation (36%) or confined to wheelchair (10%). 
They observed an improvement of motor functions which per-
sisted in time as demonstrated by the group of patients treated for 
over 36 months. Six patients discontinued ventilation and 22 cas-
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Introduction 
Pompe disease also known as glycogen storage disease type 
II (GSD type II) is a lysosomal disorder due to alfa-glucosidase 
deficiency, a key enzyme in glycogen degradation. The juve-
nile and adult forms, considered late-onset GSDII, are mainly 
characterized by slowly progressive muscle disorders mimick-
ing limb-girdle dystrophies or inflammatory myopathies, and 
or by respiratory involvement with diaphragmatic paralysis and 
restrictive respiratory insufficiency.
The histopathological hallmark is revealed by increased 
muscle fiber vacuolization with vacuoles filled of PAS-positive 
material and by strong reaction for lysosomal acid phosphatase. 
The degree of vacuolization is extremely variable in late-onset 
patients, and seems independent from age of onset, disease du-
ration, or clinical features. 
In the last few years, major advances in this field have 
been represented by the development and manufacturing of re-
combinant human GAA (rhGAA) produced and purified from 
Chinese hamster ovary cells (CHO) for enzyme replacement 
therapy (ERT). 
Clinical trials of ERT in late-onset patients 
In 2006 human acid α-glucosidase (alglucosidase alfa, My-
ozyme, Genzyme Corporation, Framingham, MA) has received 
broad-label marketing approval in Europe and, later, in the U.S. 
This type of treatment has already been applied to other lyso-
somal disorders but it represents the first attempt of targeting 
recombinant enzyme to skeletal muscle. 
Although it has been demostrated that ERT is effective in 
infantile  form,  improving  respiratory  failure  and  prolonging 
children’s survival, informations on ERT efficacy in late-onset 
GSDII forms remain still limited. 
In 2004, Winkel et al reported a 3-year follow-up study for 
3 late-onset patients (aged 11, 16, and 32 years). Those patients 
started therapy with rhGAA from milk of transgenic rabbits, but 207
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tile form, some limitations have emerged in late onset patients 
treated with ERT. However it is worthy to hypothesize that com-
bination of two or more therapeutic strategies (ERT/induction 
of imuno tolerance, ERT/chaperone, ERT/SRT) could be more 
effective in GSDII patients.
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According to the Union Européenne des Médecines Spé-
cialistes (UEMS), Section of Physical and Rehabilitation Medi-
cine, rehabilitation is the medical specialty concerning with 
the promotion of physical and cognitive functioning, activities, 
participation and modifying personal and environmental fac-
tors (1). This definition is in accordance with the International 
Classification of Functioning, Disability and Health published 
in 2002 by the World Health Organization (2). Rehabilitation 
activities require a holistic approach through the preparation of 
an individual rehabilitation project and its implementation by 
one or more rehabilitative programs containing the immediate 
and intermediate objectives and the final functional outcome. To 
settle the individual rehabilitation project it is first important to 
define the functional limitations and social participation restric-
tions of the patient using specific assessment scales. The com-
prehensive assessment of the person affected by a metabolic 
myopathy should include the evaluation of the following items: 
a. trunk and upper and lower limbs ROM (Range of Motion); b. 
upper and lower limbs strength with the MMT (Manual Muscle 
es significantly reduced the number of hours/day in ventilation. 
In this cohort of patients cardiac hypertrophy was seen in 14% of 
juvenile-adult cases, this enhances the importance of regular car-
diac evaluation, even in adult patients. This large follow up study 
confirmed and extended the previous positive observations about 
efficacy and safety on late-onset GSDII patients (5).
Side effects of rhGAA
In all the above mentioned studies adverse events in pa-
tients on ERT were mild to moderate and infusion-related or 
during the first 2 hours post-infusion. No ERT related death 
occurred.  Immunological  responses  were  seen  in  the  major-
ity of the patients, who developed anti-rhGAA IgG antibodies 
within the first 3 months of ERT that limited the treatment ef-
ficiacy (4, 5).
Experimental therapies
Different therapeutic approaches are ongoing as alternative 
or associated treatment to ERT.
In particular, gene therapy for Pompe disease has been ex-
plored by several groups. The feasibility of this approach was 
firstly shown in vitro studies using retroviral and adenoviral 
vectors expressing human GAA. In order to improve the effi-
cacy of the viral vectors and minimize the immune response, 
several approaches have been tried : modification of the GAA 
cDNA sequence, different promoters, and different AAV sero-
types (6).
Enzyme enhancement therapy (EET) is based on the ability 
of pharmacological chaperones/active site inhibitors to rescue 
mis-folded or unstable proteins from ER-associated degradation 
by increasing the amount of protein that passes the cell’s qual-
ity control system. Various inhibitors and derivatives of deox-
ynojirimycin (DNJ) have been tested in other lysosomal storage 
diseases. A number of missense mutations found in late-onset 
Pompe patients result in retention and premature degradation of 
the GAA precursor in the ER. These mutations may be amena-
ble to chaperone-mediated therapy (7).
Another  treatment  approach  under  observation  is  based 
on the enhanced delivery of the therapeutic enzyme. Currently 
available preparations of rhGAA contains a relatively low num-
ber of M6P residues. In order to improve the delivery of the 
therapeutic enzyme and to facilitate a reduction of the drug dos-
age, a second generation of the rhGAA (neo-rhGAA) with a 
higher affinity for the CI-MPR was made. This process involves 
a chemical conjugation to rhGAA of an oligosaccharide ligand 
bearing M6P residues in the optimal configuration (8).
A recent therapeutic have emerged as a possibile relevant 
option  to  be  combined  with  ERT,  called  substrate  reduction 
therapy (SRT). It aims to decrease of the amount of glycogen, 
modulating glycogen synthesis. Glycogen synthesis (GYS) can 
be modulated by mTOR which is the mammalian target of ra-
pamacin. A GAA-KO mice treated with rapamacin, exhibited a 
significant decrease of muscular glycogen due to the phosphor-
ylation-mediated inhibition of GYS1 (8).
Conclusions
So  far,  ERT  is  the  only  approved  treatment  for  Pompe 
disease. Whereas  impressive  results  were  obtained  in  infan-